The importance of the hepatic venous pressure gradient (HVPG) in selecting patients with hepatocellular carcinoma (HCC) for liver resection (LR) has been somewhat controversial. Recently, Boleslawski et al. prospectively evaluated a cohort of 40 patients undergoing LR for HCC; the authors aimed to identify the impact of HVPG values and clinical signs of portal hypertension (esophageal varices or splenomegaly with a platelet count ,100,000/mm 3 ) on postoperative outcomes (1) . The study showed that liver dysfunction and 90-day postoperative mortality rates were associated with high HVPG values (p = 0.017 and 0.026, respectively). In contrast, the presence of clinical features of portal hypertension was not associated with either liver dysfunction or shortterm mortality. The authors concluded that the HVPG should be measured routinely in HCC patients prior to LR. Clinical practice guidelines from the European Association for the Study of the Liver (EASL) and the American Association for the Study of Liver Diseases (AASLD) suggest that clinical parameters can be used as an alternative to HPVG in determining the presence of clinically relevant portal hypertension (2, 3) . Consequently, HVPG assessment may not be necessary in all LR candidates (4) . Although the Boleslawski et al. study examined an important aspect of LR for HCC patients, some concerns should be addressed.
There is no clear maximum tumor size that contraindicates LR in HCC patients with a single nodule (2, 3) . Nevertheless, in a patient with well-preserved liver function and a single tumor up to 5 cm, the presence of portal hypertension is accepted as an adverse prognostic factor that is associated with reduced and long-term patient survival (5, 6) . In 1996, Bruix et al. first reported the negative impact of significant portal hypertension on liver resection outcomes (5). Twenty-nine cirrhotic Child-Turcotte-Pugh (CPT) class A patients who underwent LR were evaluated to determine the role of increased portal pressure in developing postoperative hepatic decompensation. Eleven of the 29 patients developed persistent liver decompensation within the first three months after surgery, and HVPG was the only independent factor that predicted hepatic decompensation in a multivariate analysis (p,0.001). Subsequently, the same researchers updated their results, suggesting that either HVPG or clinical signs of portal hypertension could be used to select HCC patients for resection or liver transplantation (6) . Note that patients with a single tumor .5 cm do not fulfill the Milan criteria, and liver transplantation is not usually considered a treatment alternative (2, 3, 7) . Therefore, the presence of portal hypertension as an absolute criterion for selecting patients for liver transplantation, rather than resection, is of most relevance to the subgroup of patients who could undergo either resection or transplantation. Given the limited efficacy of other treatment options for this patient subset, such as transarterial chemoembolization, patients with a single tumor .5 cm may still be best served by liver resection, even in the presence of portal hypertension. The study by Boleslawski et al. did not mention tumor number or size in the 40 enrolled patients, and this information may aid in interpreting their data and conclusions. Note that in their series, not all of the patients performed poorly (despite liver resection in the presence of a HVPG .10 mmHg), and portal hypertension clinically-based (PH-CB) was not predictive of patient outcomes.
In light of the uncertainties surrounding the role of portal hypertension in selecting HCC patients for liver resection, we recently undertook a multicenter (in Australia, Spain, and Brazil), exploratory analysis of 105 CPT A HCC patients (with a single nodule #5 cm on imaging) who were treated with primary liver resection (unpublished data). After a median follow up of 51 months (range, 1-159 months), the 1-, 3-, and 5-year survival rates were 97%, 83%, and 66%, respectively. As in other studies, significant portal hypertension was defined as having an HVPG $10 mmHg or the presence of gastroesophageal varices, splenomegaly (spleen length $12 cm) with a platelet count ,100,000/mm 3 , or the need for diuretics to control ascites. PH-CB was defined with the same criteria but without the HVPG variable. No pre-operative characteristic predicted the likelihood of survival after assessing all of the variables recommended by the Panel of Experts in HCC-Design Clinical Trials (7) . In other words, our results suggest that liver resection for CPT A HCC patients with a single tumor #5 cm offers survival rates similar to liver transplantation, independent of any pre-operative characteristics (8) .
We have summarized the published studies evaluating liver resection for patients with cirrhosis and HCC (Table 1) . It is clear that the data regarding the prognostic factors for HCC Table 1 -Results of a series evaluating liver resection in patients with hepatocellular carcinoma and cirrhosis. .70 yrs = 48 This study was primarily designed to compare LR according to age (#70 yrs, n = 177) and (.70 yrs, n = 64). The survival rates were similar between the groups (p = 0.081).
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Retrospective Abbreviations: SPH, significant portal hypertension; BL, serum total bilirubin; HCC, hepatocellular carcinoma; LR, liver resection; LT, liver transplantation; CPT, Child-Pugh-Turcotte; N/A, not available; HE, hepatic encephalopathy; PEI, percutaneous ethanol injection; TACE, transarterial chemoembolization; ICGR15, indocyanine green retention rate at 15 minutes; MC, Milan criteria; LRFA, laparoscopic radiofrequency ablation. patients undergoing liver resection are scarce. Current recommendations for patient selection for liver resection versus liver transplantation for tumors #5 cm are still based on the original Barcelona group publication, which was based on a retrospective analysis of a case series from the 1990s (5) . Note that given the limitations of retrospective studies, the robustness of evidence supporting this finding must be validated following evidenced-based ranking systems (9) . Basing recommendations on the results of liver resection performed in the 1990s ignores recent improvements in the perioperative care of cirrhotic patients (10). These recommendations may also limit access to liver resection for patients who have no or limited access to liver transplantation.
In conclusion, further well-designed trials are warranted to evaluate the role of significant portal hypertension in predicting liver resection outcomes for HCC patients. Nevertheless, until further well-designed prospective studies are undertaken, the recommendations of the EASL-HCC Clinical Practice Guidelines should remain in place.
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